Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aardvark Therapeutics, Inc.

NASDAQ: AARD · Life Sciences · 5 alerts · CIK 1774857

Share price
$1.26Close, Nov 16
Market cap
$27.6M
Shares outstanding
21.89MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aardvark Therapeutics, Inc. filings on SEC EDGAR ↗

8:18 AM ET 8-K
Financial Results

Aardvark Therapeutics Financial Results

Aardvark Therapeutics reported Q3 2026 financial results and announced that the FDA has lifted the clinical hold on its lead candidate ARD-101 for Prader-Willi Syndrome. The company ended the quarter with $60.3 million in cash, which is expected to fund operations through 2027 as it prepares for a clinical development meeting with the FDA in early 2027.

Term
Q3 2026

“The lifting of the clinical hold and the FDA’s agreement that we may conduct an open-label trial at 200 mg twice daily are important steps toward resuming clinical development of ARD-101 in PWS. We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”

Tien Lee, M.D., Founder and Chief Executive Officer
6:04 AM ET 10-Q
Financial Results

Aardvark Therapeutics Q3 2026 Results: Net Loss of $19.2M, Loss Widens

Aardvark Therapeutics reported a net loss of $19.2 million for the third quarter of 2026, driven by increased research and development costs. The company's cash position remains at $60.3 million as it continues to transition from its 2025 initial public offering to fund its clinical-stage metabolic disease pipeline.

Key figure
Net loss $19.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.